There are no approved treatments for chronic antibody mediated rejection (ABMR).
| INTRODUCTION
Despite chronic antibody mediated rejection (ABMR) constituting one of the main reasons for late graft failure, [1] [2] [3] there are no approved drugs for its prevention or treatment. 4 Chronic ABMR is characterized by a silent clinical evolution that can delay its diagnosis. 5, 6 Criteria to define chronic ABMR have been modified since its description in 2005. 7 Originally, its diagnosis required C4d deposition in peritubular capillaries in addition to suggestive histological lesions and the presence of donor-specific antibodies (DSA). The most characteristic morphologic lesion of chronic ABMR is transplant glomerulopathy, despite it is not specific. [8] [9] [10] [11] Later on, criteria for chronic ABMR were finetuned and C4d deposition was no longer a condition for its diagnosis provided there was evidence of microcirculation inflammation.
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Information on the efficacy of treatments for ABMR is scarce and the majority of data come from small retrospective series, mainly focused on the treatment of acute ABMR. A meta-analysis reviewing the efficacy of treatments for acute ABMR showed that the evidence for efficacy is low or very low for the most commonly employed treatments. 13 Some retrospective series have shown that a combination of treatments including antibody removal, intravenous immunoglobulins (IVIG), rituximab (RTX), eculizumab, or bortezomib are associated with the amelioration of renal function in a proportion of patients.
14 However, these patients are at increased risk for chronic ABMR and the beneficial effect of reversing acute renal functional deterioration is limited in the long-term follow-up.
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The efficacy of different treatments employed to treat chronic ABMR is unclear. Some small, uncontrolled studies suggest a beneficial effect of the combined treatment based on IVIG and RTX. 16, 17 However, to the best of our knowledge no trials to test the efficacy and safety of this treatment have been performed. Thus, we conducted a multicenter, prospective, randomized, placebo-controlled, double-blind clinical trial to evaluate the efficacy and safety of IVIG combined with RTX in patients with chronic ABMR displaying transplant glomerulopathy and DSA.
| PATIENTS AND METHODS

| Study design
The Triton study was a phase IIb, multicenter, prospective, rand- The main objective was to assess the effect of combined treatment with IVIG and RTX on the evolution of renal function in patients with chronic ABMR 1 year after randomization. The primary efficacy variable was the difference in estimated glomerular filtration rate (eGFR) according to the isotope dilution mass spectrometry (IDMS) trace- 
| Study population
Patients eligible for the study were renal transplants with biopsyproven chronic ABMR diagnosed less than 6 months before rand- 
| Randomization and intervention
Patients were randomized 1:1 to the treatment and control arms by 
| Other interventions
Patients included into the trial not receiving a tacrolimus and mycophenolate mofetil treatment were switched to this treatment before randomization (target tacrolimus through levels 5-10 ng/mL).
Patients with proteinuria >0.5 g/day received an angiotensin converting enzyme inhibitor/angiotensin II receptor blocker.
| Study variables
A baseline visit before randomization and follow-up visits at 1, 3, The diagnostic renal biopsy done before the inclusion in the clinical trial and the 12-month control biopsy were employed to evaluate progression of histological damage. Biopsies were done under ultrasound guidance using a spring-loaded 16-18 G needles and two cores of tissue were evaluated. One core was used for optical microscopy and the other for immunofluorescence studies. Biopsies were processed for routine light microscopy and stained with hematoxilin-eosin, periodic acid Schift (PAS), and Masson's trichrome. Histological lesions were evaluated according to the Banff criteria at each participating center.
C4d staining was done as per local practice in each center.
| Sample size
At the time of the study design there was scarce information on the evolution of renal function in patients with chronic ABMR treated with IVIG and RTX. In the study of Billing et al, 16 
| Statistics
Baseline data between treatment groups were compared in the 
| RESULTS
| Patients
The present study was conducted between March 2012 and November 2015. The study was stopped before recruiting the planned sample size due to budget restrictions and a lower inclusion rate than expected. A total of 25 out of 26 patients assessed for eligibility were randomized; 13 were allocated to the placebo group and 12 to the treatment group. One patient allocated to placebo was withdrawn due to uremic cardiac tamponade requiring dialysis initiation 2 weeks after randomization and did not receive the assigned treatment. A second patient allocated to the treatment group withdrew consent before receiving any dose of the study drugs. The CONSORT flow diagram of the progress through the study is shown in Figure 1 . Demographic characteristics of donor and recipients as well as transplant-related variables were not different between groups (Table 1) . During follow-up, one patient from the treatment group and one from the placebo group lost their grafts at 8 and 9 months, respectively.
| Baseline biopsy and donor specific antibodies
In the baseline biopsy, transplant glomerulopathy, microcirculation inflammation (glomerulitis and peritubular capillaritis), C4d deposition, and tubulo-interstitial inflammation were not different between groups (Table 2) .
Central evaluation of DSA confirmed that all patients presented DSA at baseline. One patient in the placebo group had class I and 12 class II DSA. In the treatment group, one patient showed class I, 10
class II, and one class I+II DSA. The MFI of the immunodominant DSA was not different between groups (Table 1) .
| Primary efficacy variable
Mean eGFR at 1 year declined from 46. Serum creatinine at one year increased from 1.6 ± 0.5 to 2.1 ± 1.2 (P = .098) in the placebo group and from 2.5 ± 1.9 to 2.8 ± 1.2 (P = .075) in the treatment group. The mean difference between 1-year and baseline serum creatinine was not different between groups (0.6 ± 1.1 for the placebo group and 0.2 ± 2.1 mg/dL for the treatment group; P-value = .287).
| Secondary efficacy variables
Daily proteinuria increased in both arms (Figure 3 ) during the study period and the mean difference between 1-year and baseline daily proteinuria was not different between groups (0.9 ± 2.1 g/day for the placebo group and 0.9 ± 2.1 for the treatment group; P-value = .378).
At 1 year a renal biopsy with sufficient tissue was obtained in 10 patients in the placebo and seven patients in the treatment group. In the placebo group, the 1-year biopsy was not done because of graft failure (n = 1) and declined consent (n = 1). Similarly, in the treatment Placebo Treatment group, the 1-year biopsy was not available because of graft failure (n = 1), insufficient sample (n = 1), and declined consent (n = 2). There were no differences in histological Banff scores between study groups at 1 year. The severity of histological lesions did not significantly change between baseline and 1 year biopsy in both groups (Table 3 ).
The MFI of the immunodominant DSA was not different between groups at the end of the study and did not change between baseline and 1-year determination in the placebo or treatment group as shown in Figure 4 . The number of circulating B lymphocytes decreased after the RTX infusion in the treatment group while it remained stable in the control group ( Figure 5 ). Tacrolimus trough levels during the study period were not different between groups (Figure 6 ).
| Safety
The number of adverse events during the study period was not different in the placebo and treatment groups (28 vs. 26) . There were no episodes of opportunistic infections. During the study period, four patients in the placebo group required hospitalization due to acute diverticulitis (n = 1), acute gastroenteritis with acute renal failure (n = 2), and esophagus perforation with mediastinal abscess (n = 1). Similarly, during the study period, five patients from the treatment group required hospitalization due to urinary sepsis associated with urinary tract neoplasia and pulmonary thromboembolism (n = 1), auto-limited fever with negative cultures (n = 1), urinary tract infection (n = 2), and hyponatremia (n = 1).
| DISCUSSION
In the present trial we evaluated whether IVIG and RTX treatment delays the rate of renal function decline in patients with chronic ABMR. We considered the presence of transplant glomerulopathy an inclusion criterion as an attempt to select a homogeneous population. However, transplant glomerulopathy reflects advanced tissue antibody-mediated damage and, accordingly, only patients with evolved chronic ABMR were included.
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The primary efficacy variable was the rate of eGFR decline during the first year and it was not different between the treatment and placebo groups, suggesting that the combination of IVIG and RTX does not stabilize renal function in patients with chronic ABMR displaying transplant glomerulopathy. However, this result has to be interpreted with caution. We planned to include a total of 50 patients and finally only 26 cases were included due to budget restrictions and a lower recruitment rate than expected, leaving the study underpowered.
Originally, sample size was estimated to detect an eGFR difference of 10 ± 10 ml/min per 1.73 m 2 between groups. Our hypothesis was based in retrospective studies 16, 17 in which patients with or without transplant glomerulopathy were included. Later on, a larger study 21 showed that the rate of eGFR decline 6 months after treatment significantly improved, but especially in patients without transplant glomerulopathy. Thus, we cannot discard that the lack of response in our trial may be due to the selection of a population with too advanced histological damage. However, if we assume that treatment was ineffective, the rate of decline of eGFR estimated by the mixed linear model during one year in our patients with chronic ABMR diagnosed by means of a biopsy for cause was −6.95 ± 7.94 mL/min per 1.73 m cg-score 1.6 ± 1.1 1.9 ± 0.9 .360 2.0 ± 1.0 2.6 ± 0.9 .160 mm-score 0.9 ± 0.7 0.9 ± 1.2 .873 0.3 ± 0.5 1.5 ± 1.0 .052
ci-score 1.3 ± 0.7 1.1 ± 0.9 .619 1.9 ± 0.7 1.6 ± 0.8 .414
ct-score 1.1 ± 0.6 1.4 ± 0.8 .257
1.6 ± 0. Patients were randomized to receive eculizumab during 6 months and followed for an additional 6-month period, while the control group was not treated. In this study, there was a trend for renal function stabilization (P = .09) in the eculizumab group during the treatment period. The total number of included patients was lower than planned due to budget constraints and unanticipated difficulty recruiting patients. Bortezomib has also been tested in chronic ABMR. The
Borteject study 27 is a randomized prospective trial aimed to evaluate bortezomib versus placebo in chronic ABMR occurring after 6 months and the Tribute study (NCT02201576) randomized patients with chronic ABMR to treatment with plasma exchange, steroids, and IVIG versus the same schedule associated with two cycles of bortezomib.
Results are not available for either trial. Finally, tocilizumab, an anti IL6 receptor monoclonal antibody, was evaluated in an open study as a recue therapy for 36 patients with chronic ABMR who did not respond to their standard of care (plasma exchange, IVIG, and RTX). After treatment, there was a reduction in the MFI of the immunodominant DSA, stabilization of renal function, and amelioration of microcirculatory lesions. 28 Altogether, these data show that the number of trials done at present to treat chronic ABMR is insufficient if we take into consideration that it is one of the main reasons for late graft failure.
Additionally, the sample size is rather small and the recruitment time is longer than expected. In fact, all these trials are investigator driven and face budget restrictions due to the high cost of employed medications. Thus, lack of investment constitutes one of the major barriers to develop efficient treatments for chronic ABMR.
In conclusion, our study suggests that treatment with IVIG and RTX does not significantly modify the natural history of chronic ABMR with transplant glomerulopathy. Furthermore, the absence of any effect on circulating DSA suggests that this treatment may also be not efficient in patients with chronic ABMR diagnosed at earlier stages.
